IceCure Medical Ltd. Showcases ProSense® Cryoablation Technology at CIRSE Annual Meeting
Reuters
Sep 22
IceCure Medical Ltd. Showcases ProSense® Cryoablation Technology at CIRSE Annual Meeting
IceCure Medical Ltd. will participate in the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting from September 13-17, 2025, in Barcelona, Spain. The company will present its ProSense® cryoablation technology, which uses liquid nitrogen to destroy tumors, focusing especially on its application for breast cancer patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN79822) on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.